Advertisement

Pediatrics Cancers

  • Nicholas G. ZaorskyEmail author
  • Daniel M. Trifiletti
  • Christine E. Hill-Kayser
Chapter

Abstract

This chapter discusses the general management of patients with various pediatric solid tumors, with special focus on principles that guide radiotherapy management. Several key components of pediatric cancer care are discussed.

Keywords

Medulloblastoma Wilms’ tumor Neuroblastoma Lymphoma Pediatric Rhabdomyosarcoma 

References

  1. 1.
    Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102:1083–95.CrossRefGoogle Scholar
  2. 2.
    Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood. 2007;109:926–35.CrossRefGoogle Scholar
  3. 3.
    Anghelescu DL, Faughnan LG, Jeha S, et al. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57:1147–53.CrossRefGoogle Scholar
  4. 4.
    Martinez-Monge R, Gomez-Iturriaga A, Cambeiro M, et al. Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer. Brachytherapy. 2009;8:26–33.CrossRefGoogle Scholar
  5. 5.
    Cook B DT: Wikibooks Radiation Oncology. https://en.wikibooks.org/wiki/Radiation_Oncology. Accessed April 2018.
  6. 6.
    Edge S, Byrd D, Compton C, et al. AJCC cancer staging manual. New York: Springer; 2010.Google Scholar
  7. 7.
    Hansen E, Roach M. Handbook of evidence-based radiation oncology. 2nd ed. New York: Springer; 2010.CrossRefGoogle Scholar
  8. 8.
    Hristov B, Lin SH, Christodouleas JP. Radiation oncology – a question based review. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2014.Google Scholar
  9. 9.
    Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol. 2009;27:5182–8.CrossRefGoogle Scholar
  10. 10.
    Crist W, Gehan EA, Ragab AH, et al. The third intergroup rhabdomyosarcoma study. J Clin Oncol. 1995;13:610–30.CrossRefGoogle Scholar
  11. 11.
    Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091–102.CrossRefGoogle Scholar
  12. 12.
    Maurer HM, Beltangady M, Gehan EA, et al. The intergroup rhabdomyosarcoma study-I. A final report. Cancer. 1988;61:209–20.CrossRefGoogle Scholar
  13. 13.
    Maurer HM, Gehan EA, Beltangady M, et al. The intergroup rhabdomyosarcoma study-II. Cancer. 1993;71:1904–22.CrossRefGoogle Scholar
  14. 14.
    Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first intergroup study. J Clin Oncol. 1990;8:1664–74.CrossRefGoogle Scholar
  15. 15.
    Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer. 2012;59:5–10.CrossRefGoogle Scholar
  16. 16.
    Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990;8:1514–24.CrossRefGoogle Scholar
  17. 17.
    Donaldson SS, Torrey M, Link MP, et al. A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:125–35.CrossRefGoogle Scholar
  18. 18.
    Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701.CrossRefGoogle Scholar
  19. 19.
    Heyn RM, Holland R, Newton WA Jr, et al. The role of combined chemotherapy in the treatment of rhabdomyosarcoma in children. Cancer. 1974;34:2128–42.CrossRefGoogle Scholar
  20. 20.
    Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003;55:168–77.CrossRefGoogle Scholar
  21. 21.
    Schuck A, Rube C, Konemann S, et al. Postoperative radiotherapy in the treatment of Ewing tumors: influence of the interval between surgery and radiotherapy. Strahlenther Onkol. 2002;178:25–31.CrossRefGoogle Scholar
  22. 22.
    D’Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms’ tumor. Results of the Third National Wilms’ tumor study. Cancer. 1989;64:349–60.CrossRefGoogle Scholar
  23. 23.
    D’Angio GJ, Evans A, Breslow N, et al. The treatment of Wilms’ tumor: results of the Second National Wilms’ tumor study. Cancer. 1981;47:2302–11.CrossRefGoogle Scholar
  24. 24.
    D’Angio GJ, Evans AE, Breslow N, et al. The treatment of Wilms’ tumor: results of the National Wilms’ tumor study. Cancer. 1976;38:633–46.CrossRefGoogle Scholar
  25. 25.
    Green DM, Breslow NE, Beckwith JB, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms’ tumor: a report from the National Wilms’ tumor study group. J Clin Oncol. 1998;16:237–45.CrossRefGoogle Scholar
  26. 26.
    Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23:7312–21.CrossRefGoogle Scholar
  27. 27.
    de Kraker J, Lemerle J, Voute PA, et al. Wilms’ tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee. J Clin Oncol. 1990;8:1187–90.CrossRefGoogle Scholar
  28. 28.
    Ruteshouser EC, Huff V. Familial Wilms tumor. Am J Med Genet C Semin Med Genet. 2004;129c:29–34.CrossRefGoogle Scholar
  29. 29.
    Breslow N, Olshan A, Beckwith JB, et al. Epidemiology of Wilms tumor. Med Pediatr Oncol. 1993;21:172–81.CrossRefGoogle Scholar
  30. 30.
    Castleberry RP, Kun LE, Shuster JJ, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol. 1991;9:789–95.CrossRefGoogle Scholar
  31. 31.
    London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 2005;23:6459–65.CrossRefGoogle Scholar
  32. 32.
    Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–73.CrossRefGoogle Scholar
  33. 33.
    Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25:1054–60.CrossRefGoogle Scholar
  34. 34.
    Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol. 1988;6:1271–9.CrossRefGoogle Scholar
  35. 35.
    Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer. 1997;33:2121–5.CrossRefGoogle Scholar
  36. 36.
    Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology. 1997;104:2101–11.CrossRefGoogle Scholar
  37. 37.
    Chantada G, Doz F, Antoneli CB, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47:801–5.CrossRefGoogle Scholar
  38. 38.
    Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262–7.CrossRefGoogle Scholar
  39. 39.
    Duffner PK, Horowitz ME, Krischer JP, et al. The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro-Oncology. 1999;1:152–61.CrossRefGoogle Scholar
  40. 40.
    Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol. 1999;17:2127–36.CrossRefGoogle Scholar
  41. 41.
    Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352:978–86.CrossRefGoogle Scholar
  42. 42.
    Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18:3004–11.CrossRefGoogle Scholar
  43. 43.
    Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17:832–45.CrossRefGoogle Scholar
  44. 44.
    Brandes AA, Franceschi E, Tosoni A, et al. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer. 2007;110:2035–41.CrossRefGoogle Scholar
  45. 45.
    Koshy M, Rich S, Merchant TE, et al. Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma. J Neuro-Oncol. 2011;105:583–90.CrossRefGoogle Scholar
  46. 46.
    Merchant TE, Li C, Xiong X, et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol. 2009;10:258–66.CrossRefGoogle Scholar
  47. 47.
    Rogers L, Pueschel J, Spetzler R, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg. 2005;102:629–36.CrossRefGoogle Scholar
  48. 48.
    Calaminus G, Kortmann R, Worch J, et al. SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro-Oncology. 2013;15:788–96.CrossRefGoogle Scholar
  49. 49.
    Rogers SJ, Mosleh-Shirazi MA, Saran FH. Radiotherapy of localised intracranial germinoma: time to sever historical ties? Lancet Oncol. 2005;6:509–19.CrossRefGoogle Scholar
  50. 50.
    Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation--a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. J Clin Oncol. 1996;14:2908–15.CrossRefGoogle Scholar
  51. 51.
    Stripp DC, Maity A, Janss AJ, et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. Int J Radiat Oncol Biol Phys. 2004;58:714–20.CrossRefGoogle Scholar
  52. 52.
    Regine WF, Kramer S. Pediatric craniopharyngiomas: long term results of combined treatment with surgery and radiation. Int J Radiat Oncol Biol Phys. 1992;24:611–7.CrossRefGoogle Scholar
  53. 53.
    Winkfield KM, Linsenmeier C, Yock TI, et al. Surveillance of craniopharyngioma cyst growth in children treated with proton radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:716–21.CrossRefGoogle Scholar
  54. 54.
    Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro-Oncology. 2011;13:410–6.CrossRefGoogle Scholar
  55. 55.
    Edwards MS, Wara WM, Urtasun RC, et al. Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. J Neurosurg. 1989;70:691–700.CrossRefGoogle Scholar
  56. 56.
    Greenberg ML, Fisher PG, Freeman C, et al. Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. Pediatr Blood Cancer. 2005;45:644–8.CrossRefGoogle Scholar
  57. 57.
    Jalali R, Raut N, Arora B, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77:113–8.CrossRefGoogle Scholar
  58. 58.
    Janssens GO, Jansen MH, Lauwers SJ, et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys. 2013;85:315–20.CrossRefGoogle Scholar
  59. 59.
    Skowronska-Gardas A. A literature review of the recent radiotherapy clinical trials in pediatric brain tumors. Rev Recent Clin Trials. 2009;4:42–55.CrossRefGoogle Scholar
  60. 60.
    Janssens GO, Gidding CE, Van Lindert EJ, et al. The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int J Radiat Oncol Biol Phys. 2009;73:722–6.CrossRefGoogle Scholar
  61. 61.
    Negretti L, Bouchireb K, Levy-Piedbois C, et al. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution’s experience. J Neuro-Oncol. 2011;104:773–7.CrossRefGoogle Scholar
  62. 62.
    Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012;44:251–3.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nicholas G. Zaorsky
    • 1
    Email author
  • Daniel M. Trifiletti
    • 2
  • Christine E. Hill-Kayser
    • 3
  1. 1.Penn State Cancer InstituteHersheyUSA
  2. 2.Mayo ClinicJacksonvilleUSA
  3. 3.University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations